BioNTech SE (NASDAQ:BNTX) is one of the best healthcare stocks to buy with highest upside potential.
BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Company announced on May 30 interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer
The company reported that the data showed “encouraging anti-tumor activity, with high response rates observed in both non-squamous and squamous NSCLC and at each PD-L1 expression level”. Solange Peters, M.D., Ph.D., Lead Investigator and Director of Oncology at the University Hospital of Lausanne, Switzerland, stated that they are “encouraged by the efficacy signal with this bispecific approach, showing robust responses across subtypes and PD-L1 levels, supporting the continued investigation of pumitamig and its potential to deliver improved outcomes for a broad range of patients with NSCLC.” In a separate development, UBS upgraded BioNTech SE (NASDAQ:BNTX) to Buy from Neutral on May 27, lifting the price target on the stock to $135 from $117. While we acknowledge the potential of BNTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow. Disclosure: None.